诚意药业：目前公司已获批的二十碳五烯酸乙酯软胶囊的原料药为外部采购

Core Viewpoint - Chengyi Pharmaceutical (603811) has confirmed that the raw materials for its approved product, ethyl eicosapentaenoate soft capsules, are currently sourced externally and is undergoing workshop compliance inspection, with expected sales starting in 2026 [1] Group 1 - The company has received approval for ethyl eicosapentaenoate soft capsules [1] - The raw materials for this product are being procured from external suppliers [1] - The product is currently in the workshop compliance inspection phase [1] - Sales are anticipated to begin in 2026 [1]